Comorbidity of substance use and mental disorders in Europe
This publication looks at the co-occurrence of drug use problems and mental health disorders, taking in the theoretical background of psychiatric comorbidity, the tools for clinical diagnosis and the prevalence and clinical relevance of the problem in Europe.
Drugnet Europe 92
In this issue: Lisbon Addictions 2015 — conference round-up | Sponsored sessions at Lisbon Addictions 2015 | EMCDDA 20 years of monitoring conference | EMCDDA signs Memorandum of Understanding with Georgia | Minimum quality standards for drug demand reduction interventions in the EU |New EMCDDA products and services | EMCDDA scientific paper award
Report on the risk assessment of 4,4-DMAR
This publication presents the data and findings of the risk assessment on 4,4’-DMAR (4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014.
Report on the risk assessment of MT-45
This publication presents the data and findings of the risk assessment on MT-45 (1-cyclohexyl-4-(1, 2-diphenylethyl)piperazine), carried out by the extended Scientific Committee of the EMCDDA on 16 September 2014.
In May 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, commonly known as α-pyrrolidinovalerophenone (α-PVP), through a joint assessment.